Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis, an infectious
disease with one of the highest morbidity and mortality rates worldwide. Leveraging its …

Drug resistance in tuberculosis (TB) is a particular problem because the lengthy therapy of
at least 6 months makes patient compliance very difficult, which frequently creates drug …

The molecular basis for isoniazid resistance in Mycobacterium tuberculosis is complex.
Putative isoniazid resistance mutations have been identified in katG, ahpC, inhA, kasA, and …

ABSTRACT The new GenoType Mycobacterium tuberculosis drug resistance second line
(MTBDR sl) assay (Hain Lifescience, Nehren, Germany) was tested on 106 clinical isolates …

Tuberculosis is a leading killer of young adults worldwide and the global scourge of multi-
drug resistant tuberculosis is reaching epidemic proportions. It is endemic in most …

Isoniazid, administered as part of combination antituberculosis therapy, is responsible for
most of the early bactericidal activity (EBA) of the regimen. However, the emergence of …

Implicated as a major mechanism of ethambutol (EMB) resistance in clinical studies of
Mycobacterium tuberculosis, mutations in codon 306 of the embB gene (embB 306) have …

Background. Ethambutol is used for the treatment of tuberculosis in cases where there is
isoniazid resistance. We examined the emergence of drug resistance to ethambutol …

The GenoType MTBDR sl test and DNA sequencing were used to rapidly detect second-line
drug-and ethambutol (EMB)-resistant Mycobacterium tuberculosis. The ability of these two …

Antimicrobial pharmacokinetic-pharmacodynamic (PK/PD) science and clinical trial
simulations have not been adequately applied to the design of doses and dose schedules of …